Your browser doesn't support javascript.
loading
Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.
Koczkowska, Magdalena; Chen, Yunjia; Callens, Tom; Gomes, Alicia; Sharp, Angela; Johnson, Sherrell; Hsiao, Meng-Chang; Chen, Zhenbin; Balasubramanian, Meena; Barnett, Christopher P; Becker, Troy A; Ben-Shachar, Shay; Bertola, Debora R; Blakeley, Jaishri O; Burkitt-Wright, Emma M M; Callaway, Alison; Crenshaw, Melissa; Cunha, Karin S; Cunningham, Mitch; D'Agostino, Maria D; Dahan, Karin; De Luca, Alessandro; Destrée, Anne; Dhamija, Radhika; Eoli, Marica; Evans, D Gareth R; Galvin-Parton, Patricia; George-Abraham, Jaya K; Gripp, Karen W; Guevara-Campos, Jose; Hanchard, Neil A; Hernández-Chico, Concepcion; Immken, LaDonna; Janssens, Sandra; Jones, Kristi J; Keena, Beth A; Kochhar, Aaina; Liebelt, Jan; Martir-Negron, Arelis; Mahoney, Maurice J; Maystadt, Isabelle; McDougall, Carey; McEntagart, Meriel; Mendelsohn, Nancy; Miller, David T; Mortier, Geert; Morton, Jenny; Pappas, John; Plotkin, Scott R; Pond, Dinel.
Afiliação
  • Koczkowska M; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Chen Y; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Callens T; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Gomes A; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Sharp A; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Johnson S; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Hsiao MC; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Chen Z; Department of Genetics, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
  • Balasubramanian M; Sheffield Clinical Genetics Service, Sheffield Children's NHS Foundation Trust, Sheffield S10 2TH, UK.
  • Barnett CP; Women's and Children's Hospital/SA Pathology, North Adelaide, SA 5006, Australia.
  • Becker TA; Medical Genetics, John Hopkins All Children's Hospital, St. Petersburg, FL 33701, USA.
  • Ben-Shachar S; The Genetic Institute, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel-Aviv 6997801, Israel.
  • Bertola DR; Department of Pediatrics, University of São Paulo, São Paulo 05403-000, Brazil.
  • Blakeley JO; Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
  • Burkitt-Wright EMM; Genomic Medicine, Division of Evolution and Genomic Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK.
  • Callaway A; Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury SP2 8BJ, UK.
  • Crenshaw M; Medical Genetics, John Hopkins All Children's Hospital, St. Petersburg, FL 33701, USA.
  • Cunha KS; Department of Pathology, School of Medicine, Universidade Federal Fluminense, Niterói 24220-900, Brazil.
  • Cunningham M; Division of Genetic, Genomic and Metabolic Disorders, Children's Hospital of Michigan, Detroit Medical Center, Detroit, MI 48201, USA.
  • D'Agostino MD; Department of Medical Genetics, McGill University Health Centre, Montréal, QC H4A 3J1, Canada.
  • Dahan K; Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies 6041, Belgium.
  • De Luca A; Molecular Genetics Unit, Casa Sollievo della Sofferenza Hospital, IRCCS, San Giovanni Rotondo 71013, Italy.
  • Destrée A; Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies 6041, Belgium.
  • Dhamija R; Department of Clinical Genomics and Neurology, Mayo Clinic, Phoenix, AZ 85259, USA.
  • Eoli M; Unit of Molecular Neuro-Oncology, IRCCS Foundation, Carlo Besta Neurological Institute, Milan 20133, Italy.
  • Evans DGR; Genomic Medicine, Division of Evolution and Genomic Sciences, Manchester Academic Health Sciences Centre, University of Manchester, Central Manchester University Hospitals NHS Foundation Trust, Manchester M13 9WL, UK.
  • Galvin-Parton P; Department of Genetics, Stony Brook Children's, Stony Brook, NY 11794, USA.
  • George-Abraham JK; Dell Children's Medical Center of Central Texas, Austin, TX 78723, USA.
  • Gripp KW; Division of Medical Genetics, Al DuPont Hospital for Children, Wilmington, DE 19803, USA.
  • Guevara-Campos J; Pediatrics Service, Felipe Guevara Rojas Hospital, University of Oriente, El Tigre-Anzoátegui, Venezuela 6034, Spain.
  • Hanchard NA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA.
  • Hernández-Chico C; Department of Genetics, Hospital Universitario Ramón y Cayal, Institute of Health Research (IRYCIS), Madrid 28034, Spain and Center for Biomedical Research-Network of Rare Diseases (CIBERER).
  • Immken L; Dell Children's Medical Center of Central Texas, Austin, TX 78723, USA.
  • Janssens S; Center for Medical Genetics, Ghent University Hospital, Ghent 9000, Belgium.
  • Jones KJ; Department of Clinical Genetics, the Children's Hospital at Westmead, Westmead, NSW 2145, Australia.
  • Keena BA; Division of Human Genetics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
  • Kochhar A; Department of Genetics, Valley Children's Healthcare, Madera, CA 93636, USA.
  • Liebelt J; Women's and Children's Hospital/SA Pathology, North Adelaide, SA 5006, Australia.
  • Martir-Negron A; Division of Clinical Genetics, Center for Genomic Medicine, Miami Cancer Institute, Miami, FL 33176, USA.
  • Mahoney MJ; Department of Genetics, Yale University, New Haven, CT 06520, USA.
  • Maystadt I; Center for Human Genetics, Institute of Pathology and Genetics (IPG), Gosselies 6041, Belgium.
  • McDougall C; Division of Human Genetics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
  • McEntagart M; St George's University Hospitals NHS Foundation Trust, London SW17 0QT, UK.
  • Mendelsohn N; Genomics Medicine Program, Children's Hospital Minnesota, Minneapolis, MN 55404, USA.
  • Miller DT; Multidisciplinary Neurofibromatosis Program, Boston Children's Hospital, Boston, MA 02115, USA.
  • Mortier G; Department of Medical Genetics, University of Antwerp and Antwerp University Hospital, Antwerp 2650, Belgium.
  • Morton J; Birmingham Women's and Children's NHS Foundation Trust, Birmingham B15 2TG, UK.
  • Pappas J; Department of Pediatrics, Clinical Genetic Services, NYU School of Medicine, New York, NY 10016, USA.
  • Plotkin SR; Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Pond D; Genomics Medicine Program, Children's Hospital Minnesota, Minneapolis, MN 55404, USA.
Am J Hum Genet ; 102(1): 69-87, 2018 01 04.
Article em En | MEDLINE | ID: mdl-29290338
Neurofibromatosis type 1 (NF1), a common genetic disorder with a birth incidence of 1:2,000-3,000, is characterized by a highly variable clinical presentation. To date, only two clinically relevant intragenic genotype-phenotype correlations have been reported for NF1 missense mutations affecting p.Arg1809 and a single amino acid deletion p.Met922del. Both variants predispose to a distinct mild NF1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors. Here, we report 162 individuals (129 unrelated probands and 33 affected relatives) heterozygous for a constitutional missense mutation affecting one of five neighboring NF1 codons-Leu844, Cys845, Ala846, Leu847, and Gly848-located in the cysteine-serine-rich domain (CSRD). Collectively, these recurrent missense mutations affect ∼0.8% of unrelated NF1 mutation-positive probands in the University of Alabama at Birmingham (UAB) cohort. Major superficial plexiform neurofibromas and symptomatic spinal neurofibromas were more prevalent in these individuals compared with classic NF1-affected cohorts (both p < 0.0001). Nearly half of the individuals had symptomatic or asymptomatic optic pathway gliomas and/or skeletal abnormalities. Additionally, variants in this region seem to confer a high predisposition to develop malignancies compared with the general NF1-affected population (p = 0.0061). Our results demonstrate that these NF1 missense mutations, although located outside the GAP-related domain, may be an important risk factor for a severe presentation. A genotype-phenotype correlation at the NF1 region 844-848 exists and will be valuable in the management and genetic counseling of a significant number of individuals.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Códon / Neurofibromatose 1 / Mutação de Sentido Incorreto / Neurofibromina 1 / Estudos de Associação Genética Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Am J Hum Genet Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Códon / Neurofibromatose 1 / Mutação de Sentido Incorreto / Neurofibromina 1 / Estudos de Associação Genética Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Child / Female / Humans / Male Idioma: En Revista: Am J Hum Genet Ano de publicação: 2018 Tipo de documento: Article